Payment overview · 2025
General Payments
$174.29
8 reported records · 5 companies
Healthcare provider profile · identity verified
Jonna Leigh Schmidt, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUDSON, MI · NPI 1841295698
Verified facts
What the public records show
CMS Open Payments records show Jonna Leigh Schmidt, MD received $174.29 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Ozempic, Shingrix, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.79 | 32.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.05 | 29.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.04 | 14.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.40 | 12.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.01 | 12.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $174.29 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.05 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 353 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
84 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
68 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
353 | 259 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
88 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 183 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 552 | 549 |
| Levothyroxine Sodium | Levothyroxine Sodium | 549 | 102 |
| Lisinopril | Lisinopril | 549 | 125 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 353 | 259 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 80 |
| Bumetanide | Bumetanide | 270 | 55 |
| Metformin Hcl | Metformin Hcl | 268 | 55 |
| Omeprazole | Omeprazole | 265 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 71 |
| Gabapentin | Gabapentin | 244 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 235 | 61 |
| Eliquis | Apixaban | 232 | 44 |
| Losartan Potassium | Losartan Potassium | 204 | 47 |
| Tramadol Hcl | Tramadol Hcl | 192 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 45 |
| Potassium Chloride | Potassium Chloride | 187 | 44 |
| Finasteride | Finasteride | 164 | 39 |
| Buspirone Hcl | Buspirone Hcl | 144 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 25 |
| Famotidine | Famotidine | 142 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 38 |
| Alendronate Sodium | Alendronate Sodium | 130 | 30 |
| Jardiance | Empagliflozin | 130 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 121 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 29 |
| Simvastatin | Simvastatin | 111 | 24 |
| Sertraline Hcl | Sertraline Hcl | 101 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 17 |
| Trazodone Hcl | Trazodone Hcl | 96 | 24 |
| Allopurinol | Allopurinol | 95 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 22 |
| Baclofen | Baclofen | 87 | 33 |
| Furosemide | Furosemide | 87 | 21 |
| Farxiga | Dapagliflozin Propanediol | 84 | 11 |
| Lorazepam | Lorazepam | 84 | 15 |
| Xarelto | Rivaroxaban | 82 | 16 |
| Glipizide Er | Glipizide | 79 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 21 |
| Amoxicillin | Amoxicillin | 76 | 59 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 76 | 76 |
| Azithromycin | Azithromycin | 73 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | suppressed |
| Atenolol | Atenolol | 72 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 26 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 68 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Cephalexin | Cephalexin | 64 | 37 |
| Spironolactone | Spironolactone | 64 | 14 |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 62 | suppressed |
| Glipizide | Glipizide | 56 | 14 |
| Lovastatin | Lovastatin | 56 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 15 |
| Carvedilol | Carvedilol | 53 | 16 |
| Phenobarbital | Phenobarbital | 51 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 21 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 11 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 45 | 45 |
| Prednisone | Prednisone | 45 | 15 |
| Meloxicam | Meloxicam | 43 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 34 |
| Dexamethasone | Dexamethasone | 40 | 34 |
| Warfarin Sodium | Warfarin Sodium | 40 | 12 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Valsartan | Valsartan | 39 | 11 |
| Cefprozil | Cefprozil | 38 | 28 |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 16 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Lacosamide | Lacosamide | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 11 |
| Lidocaine | Lidocaine | 26 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | 25 |
| Risperidone | Risperidone | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 16 |
| Methylprednisolone | Methylprednisolone | 25 | 20 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 21 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 21 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 18 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Ethosuximide | Ethosuximide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | 11 |
| Naproxen | Naproxen | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $174.29 · 8 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, INSPIRE, Ozempic, REXULTI, SHINGRIX, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error